玻璃体腔注射康柏西普治疗PCV疗效观察

Clinical Observation of Intravitreal Conbercept Injection in the Treatment of Polypoidal Choroidal Vasculopathy

目的探讨玻璃体腔注射康柏西普治疗息肉状脉络膜血管病变(PCV)的临床效果。方法回顾性分析2016年1月~2016年12月在潍坊医学院附属医院就诊的27例(27眼)确诊为PCV的患者的临床资料。玻璃体内注射康柏西普,每个月1次,连续注射3个月,必要时追加注射次数。观察患者治疗前后黄斑中心凹厚度以及患眼最佳矫正视力(BCVA)情况对比。结果治疗6个月时,中心凹视网膜厚度明显改善或稳定者占81.5%.治疗后6个月,74.0%患者维持了最佳矫正视力。结论 IVC可以减少PCV患者渗出性改变,并保持患者短期的视觉功能。

Objective To evaluate the efficacy of intravitreal injection of conbercept in the treatment of polypoidal choroidal vasculopathy（ PCV）. Methods Twenty-seven eyes of 27 patients which diagnosed as PCV in the affiliated hospital of weifang medical university between January 2016 to December 2016 were enrolled. All patients received the treatment of intravitreal of conbercept injection 3 monthly and were followed up for 6 months. Results At 6months of treatment,the retinal thickness of the center was significantly improved or stabilized by 81. 5%. Twelve months after treatment,74. 0% of patients maintained optimal corrected visual acuity. Conclusion In eyes with PCV,intravitreal conbercept injection can reduce the exudative change and can maintain visual function for at least half a year.